Volume 4, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


For the past 35 years the principal and most widely used drugs in the treatment of schistosomiasis have been two antimony compounds: tartar emetic introduced by Christopherson (1918) and stibophen (Fuadin) a sulfonated catechol-antimony complex introduced by Khalil (1929). Literally tons of these drugs have been used, largely empirically, in the treatment of this infection. The literature dealing with the subject is indeed voluminous, and as one reviews it, one cannot escape the recurring theme of pessimism in relation to the alleged shortcomings of these drugs, and one notes the oft repeated expression of hope for better drugs. The chemists and other laboratory investigators are repeatedly urged to provide such drugs, yet there are few examples of critical stock-taking on the part of the clinicans relative to the actual efficiency of the antimony compounds already available as therapeutic agents.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error